Secondary chromosomal abnormalities in acute leukemias.

Abstract:

:Secondary chromosomal aberrations reported in the literature were surveyed in acute myeloid or lymphoblastic leukemia (AML or ALL) with one of the following primary abnormalities: in AML, t(1;3), t(1;22), der(1;7), inv(3), t(3;5) +4, del(5q), t(6;9), -7, t(7;11), del(7q), +8, t(8;16), t(8;21), +9, t(9;11), del(9q), t(9;22), +11, del(11q), t(11;19), del(12p), +13, t(15;17), inv(16), t(16;21), i(17)(q10), del(20q), -21, +21, +22, and -Y; in ALL, t(1;14), t(1;19), der(19)t(1;19), t(4;11), del(6q), t(8;14)(q24;q11), t(8;14)(q24;q32), t(8;22), del(9p), dic(9;12), i(9)(q10), t(9;22), t(10;14), t(11;14), t(11;19), del(12p), -20, +21, and del(22q). Out of 7111 acute leukemias with clonal karyotypic aberrations, 2414 AMLs and 1078 ALLs had one of the selected primary chromosome rearrangements, and 40 and 49% of these AMLs and ALLs, respectively, displayed additional abnormalities. The type and frequency of these secondary changes were ascertained and then correlated with both the primary abnormality and the morphology or immunophenotype of the acute leukemia. The distribution of the secondary changes was clearly nonrandom. The most frequent numerical changes were -Y, -X, -7, +8, and +22 in AML and +X, +6, -7, +8, and +21 in ALL. The most common structural aberrations were del(5q), del(7q), and del(9q) in AML and dup(1q), i(7q)(q10), and der(22)t(9;22) in ALL. Some secondary changes were common to both disease groups, e.g. -7, +8, and +21, but several anomalies were restricted to either AML, such as -X, -5, and del(9q), or ALL, e.g. +X, i(7)(q10), and i(9)(q10). The type and frequency of the secondary aberrations varied within the AMLs and ALLs, not only among the different primary abnormality subgroups but also among the AML morphologies and the immunophenotypic maturation degrees of the ALLs. In general, the type of primary abnormality, rather than the differentiation stage of the acute leukemia, appeared to be instrumental in determining the type of secondary changes accruing. This conclusion was based on the finding that several primary abnormalities characterizing acute leukemias of the same morphology or immunophenotype displayed different patterns of secondary anomalies. The nonrandom, and sometimes quite specific, patterns of secondary aberrations strongly indicate that they are responsible for important phenotypic features of the tumor cell population, presumably closely associated with tumor progression. The molecular pathogenetic consequences of the secondary anomalies are unknown, but since most secondary changes are monosomies, trisomies, deletions, or isochromosomes resulting in genomic imbalances, one may hypothesize that gene dosage alterations rather than specific gene rearrangements are essential for tumor evolution.(ABSTRACT TRUNCATED AT 400 WORDS)

journal_name

Leukemia

journal_title

Leukemia

authors

Johansson B,Mertens F,Mitelman F

subject

Has Abstract

pub_date

1994-06-01 00:00:00

pages

953-62

issue

6

eissn

0887-6924

issn

1476-5551

journal_volume

8

pub_type

杂志文章

相关文献

LEUKEMIA文献大全
  • Configuration of the immunoglobulin and T cell receptor gene regions in hairy cell leukemia and B-chronic lymphocytic leukemia.

    abstract::The configuration of the immunoglobulin heavy and light chain genes and of the T cell receptor (TCR) beta region was examined in a series of patients with hairy cell leukemia (HCL) and compared with the findings in B cell chronic lymphocytic leukemia (B-CLL). In all cases of HCL and B-CLL studied a rearrangement of th...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Migone N,Giubellino MC,Casorati G,Tassinari A,Lauria F,Foa R

    更新日期:1987-04-01 00:00:00

  • Essential thrombocythemia--clinical features, therapy and follow-up of 12 cases.

    abstract::The authors analyzed twelve patients with symptomatic essential throthrombocythemia (E.T.) diagnosed from 1983 to 1991. Haemorrhagic and thrombotic phenomena were the main presenting features. Treatment consisted mostly of alpha-interferon (IFN-alpha 2b) subcutaneously in dosage ranging from 3 to 5 MU/m2 and hydroxyur...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Lopes E,Ribeiro MM,Silva MJ,Gandra M,Principe F,Granato C

    更新日期:1992-01-01 00:00:00

  • Recognition of the ALL-specific BCR-ABL junction in P190bcr-abl by monoclonal antibody ER-FP1.

    abstract::The pH chromosome, resulting from the t(9;22) translocation, is the most frequently observed cytogenetic aberration in acute lymphoblastic leukemia (ALL). Two genes, bcr and abl, are involved in this translocation. As a consequence, parts of the bcr and abl genes are fused, resulting in chimeric bcr-abl genes encoding...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: van Denderen J,ten Hacken P,Berendes P,Zegers N,Boersma W,Grosveld G,van Ewijk W

    更新日期:1994-09-01 00:00:00

  • A pilot study of all-trans retinoic acid in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.

    abstract::Retinoids have significant antiproliferative effect against chronic myelogenous leukemia (CML) cells in vitro. We conducted a pilot study to investigate the clinical effect of all-trans retinoic acid (ATRA) in patients with CML. Thirteen patients with Philadelphia chromosome (Ph)-positive CML in late chronic phase (n=...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2400682

    authors: Cortes J,Kantarjian H,O'Brien S,Beran M,Estey E,Keating M,Talpaz M

    更新日期:1997-07-01 00:00:00

  • Intensified chemotherapy inspired by a pediatric regimen combined with allogeneic transplantation in adult patients with acute lymphoblastic leukemia up to the age of 40.

    abstract::Event-free survival (EFS) at 5 years in pediatric acute lymphoblastic leukemia (ALL) is >80%. Outcome in adult ALL is still unsatisfactory, which is due to less cumulative dosing of chemotherapy and less strict adherence to timing of successive cycles. In the present phase II trial, we evaluated a pediatric regimen in...

    journal_title:Leukemia

    pub_type: 杂志文章,多中心研究

    doi:10.1038/leu.2011.141

    authors: Rijneveld AW,van der Holt B,Daenen SM,Biemond BJ,de Weerdt O,Muus P,Maertens J,Mattijssen V,Demuynck H,Legdeur MC,Wijermans PW,Wittebol S,Spoelstra FM,Dekker AW,Ossenkoppele GJ,Willemze R,Cornelissen JJ,Dutch-Belgian HO

    更新日期:2011-11-01 00:00:00

  • Declining rates of treatment-related mortality in patients with newly diagnosed AML given 'intense' induction regimens: a report from SWOG and MD Anderson.

    abstract::Less-intense remission induction regimens for adults with newly diagnosed acute myeloid leukemia (AML) aim to reduce treatment-related mortality (TRM), here defined as death within 4 weeks after starting induction therapy. This assumes that TRM rates are similar to the 15-20% observed 20 years ago. Herein we test this...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2013.176

    authors: Othus M,Kantarjian H,Petersdorf S,Ravandi F,Godwin J,Cortes J,Pierce S,Erba H,Faderl S,Appelbaum FR,Estey E

    更新日期:2014-02-01 00:00:00

  • Methylation analysis of the human multidrug resistance 1 gene in normal and leukemic hematopoietic cells.

    abstract::Expression of the human multidrug resistance 1 gene (MDR1), which encodes the P-glycoprotein transmembrane efflux pump, has been associated with treatment failure of some leukemias, primarily acute myeloid leukemia (AML). To elucidate the epigenetic events associated with overexpression of MDR1 in AML, we analyzed the...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2401424

    authors: Fryxell KB,McGee SB,Simoneaux DK,Willman CL,Cornwell MM

    更新日期:1999-06-01 00:00:00

  • Chloroquine induces basophilic differentiation of HL-60 cells.

    abstract::Many agents have been known to induce the differentiation of HL-60 cells. However, only a small number of reports on the basophilic differentiation of this cell line are known. In this study we show that the exposure of HL-60 cells to chloroquine induces to differentiate into basophils. This chloroquine-induced change...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Sasaki R,Furukawa Y,Okada K,Nakamura M,Yamane Y,Miura Y,Eguchi M

    更新日期:1997-04-01 00:00:00

  • A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes.

    abstract::The use of darbepoetin alfa to treat anemia in patients with lower-risk myelodysplastic syndromes (MDS) was evaluated in a phase 3 trial. Eligible patients had low/intermediate-1 risk MDS, hemoglobin ⩽10 g/dl, low transfusion burden and serum erythropoietin (EPO) ⩽500 mU/ml. Patients were randomized 2:1 to receive 24 ...

    journal_title:Leukemia

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1038/leu.2017.192

    authors: Platzbecker U,Symeonidis A,Oliva EN,Goede JS,Delforge M,Mayer J,Slama B,Badre S,Gasal E,Mehta B,Franklin J

    更新日期:2017-09-01 00:00:00

  • Lack of CD95/FAS gene somatic mutations in extranodal, nodal and splenic marginal zone B cell lymphomas.

    abstract::Germline CD95 (also known as FAS, APT1 and APO1) gene mutations have been associated with benign lymphoproliferative diseases and autoimmune processes. Somatic mutations have been reported in human tumours, including lymphomas. Since marginal zone B cell lymphomas usually arise in a background of chronic inflammation,...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2401708

    authors: Bertoni F,Conconi A,Luminari S,Realini C,Roggero E,Baldini L,Carobbio S,Cavalli F,Neri A,Zucca E

    更新日期:2000-03-01 00:00:00

  • Induction treatment of acute promyelocytic leukemia using all-trans retinoic acid. Controversies about dosage, advantages and side-effect management.

    abstract::All-trans retinoic acid (ATRA) in acute promyelocytic leukemia (APL) represents the leading example of targetted drugs for inducing an in vivo differentiation of malignancy (1,2). A fixed dose of 45 mg/m2/day was proposed for the treatment of patients (3), according to the results obtained by retinoic acid derivatives...

    journal_title:Leukemia

    pub_type: 临床试验,杂志文章

    doi:

    authors: Dombret H,Castaigne S,Fenaux P,Chomienne C,Degos L

    更新日期:1994-01-01 00:00:00

  • Pediatric acute myelogenous leukemia cells express IL-6 receptors and are sensitive to a recombinant IL6-Pseudomonas exotoxin.

    abstract::We have studied IL-6 receptor (IL-6R) expression on AML cells from 15 pediatric patients by immunocytochemistry/flow cytometry, reverse-transcription polymerase chain reaction, and Scatchard analysis. High-affinity IL-6R were detected on leukemic cells from 12 (80%) patients. Binding sites per cell ranged from 140 to ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2400914

    authors: Boayue KB,Gu L,Yeager AM,Kreitman RJ,Findley HW

    更新日期:1998-02-01 00:00:00

  • Expression and regulation of IL-4 receptors on human monocytes and acute myeloblastic leukemic cells.

    abstract::Evidence is presented that human monocytes and acute myeloblastic leukemic (AML) cells contain both high and low affinity binding sites for interleukin-4 (IL-4). On monocytes 183 +/- 132 high affinity binding sites per cell with a Kd of 60 +/- 29 pM and 1500 +/- 600 low affinity receptors with a Kd of 2.3 +/- 0.4 nM (...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Wagteveld AJ,van Zanten AK,Esselink MT,Halie MR,Vellenga E

    更新日期:1991-09-01 00:00:00

  • VEGF receptors on chronic lymphocytic leukemia (CLL) B cells interact with STAT 1 and 3: implication for apoptosis resistance.

    abstract::We have previously shown that chronic lymphocytic leukemia (CLL) B cells secrete vascular endothelial growth factor (VEGF) in vitro, have constitutively active VEGF receptors R1 and R2, and respond to exogenous VEGF by specifically upregulating Mcl-1 and XIAP in association with decreased cell death. We found that epi...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2403667

    authors: Lee YK,Shanafelt TD,Bone ND,Strege AK,Jelinek DF,Kay NE

    更新日期:2005-04-01 00:00:00

  • The modulating effect of PSC 833, cyclosporin A, verapamil and genistein on in vitro cytotoxicity and intracellular content of daunorubicin in childhood acute lymphoblastic leukemia.

    abstract::Resistance to anthracyclines is related to a poor prognosis in childhood acute lymphoblastic leukemia (ALL). Resistance to this class of drugs may (partly) be reversed by modulating agents, as has been demonstrated in a variety of cell lines. However, it is unknown which modulators may be of clinical benefit in childh...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2401035

    authors: den Boer ML,Pieters R,Kazemier KM,Janka-Schaub GE,Henze G,Veerman AJ

    更新日期:1998-06-01 00:00:00

  • Two acute monocytic leukemia (AML-M5a) cell lines (MOLM-13 and MOLM-14) with interclonal phenotypic heterogeneity showing MLL-AF9 fusion resulting from an occult chromosome insertion, ins(11;9)(q23;p22p23).

    abstract::We describe two new human leukemia cell lines, MOLM-13 and MOLM-14, established from the peripheral blood of a patient at relapse of acute monocytic leukemia, FAB M5a, which had evolved from myelodysplastic syndrome (MDS). Both cell lines express monocyte-specific esterase (MSE) and MLL-AF9 fusion mRNA. Gene fusion is...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2400768

    authors: Matsuo Y,MacLeod RA,Uphoff CC,Drexler HG,Nishizaki C,Katayama Y,Kimura G,Fujii N,Omoto E,Harada M,Orita K

    更新日期:1997-09-01 00:00:00

  • Down-regulation of c-myc gene is not obligatory for growth inhibition and differentiation of human myeloid leukemia cells.

    abstract::Suppression of c-myc expression is observed during induced differentiation of several myeloid cell lines and it has been attributed to the cell growth arrest that accompanies terminal differentiation. To dissect the role of c-Myc in the proliferation-differentiation switch we have studied c-myc expression in K562 cell...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Gómez-Casares MT,Delgado MD,Lerga A,Crespo P,Quincoces AF,Richard C,León J

    更新日期:1993-11-01 00:00:00

  • Multiple myeloma oncogene 1 (MUM1)/interferon regulatory factor 4 (IRF4) upregulates monokine induced by interferon-gamma (MIG) gene expression in B-cell malignancy.

    abstract::MUM1 (multiple myeloma oncogene 1)/IRF4 (interferon regulatory factor 4) is a transcription factor that is activated as a result of t(6;14)(p25;q32) in multiple myeloma. MUM1 expression is seen in various B-cell lymphomas and predicts an unfavorable outcome in some lymphoma subtypes. To elucidate its role in B-cell ma...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2403833

    authors: Uranishi M,Iida S,Sanda T,Ishida T,Tajima E,Ito M,Komatsu H,Inagaki H,Ueda R

    更新日期:2005-08-01 00:00:00

  • Effective in vivo induction of NKG2D ligands in acute myeloid leukaemias by all-trans-retinoic acid or sodium valproate.

    abstract::Engagement of NKG2D by their ligands (NKG2D-L), as the human major histocompatibility complex class I-related molecules MIC-A and the UL16-binding proteins, on cytolytic lymphocytes leads to the enhancement of antitumour effector functions. These ligands are missing or expressed at very low levels on leukaemic cells; ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2008.354

    authors: Poggi A,Catellani S,Garuti A,Pierri I,Gobbi M,Zocchi MR

    更新日期:2009-04-01 00:00:00

  • Deletions on der(9) chromosome in adult Ph-positive acute lymphoblastic leukemia occur with a frequency similar to that observed in chronic myeloid leukemia.

    abstract::The t(9;22)(q34;q11), generating the Philadelphia chromosome (Ph), is found in more than 90% of patients with chronic myeloid leukemia (CML) and in 15-30% of adults with acute lymphoblastic leukemia (ALL). Different groups have recently described the presence of large genomic deletions adjacent to the translocation br...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2402829

    authors: Specchia G,Albano F,Anelli L,Storlazzi CT,Zagaria A,Mancini M,Cuneo A,Pane F,Foà R,Manolelli F,Liso V,Rocchi M

    更新日期:2003-03-01 00:00:00

  • All-trans retinoic acid induces monocyte growth factor receptor (c-fms) gene expression in HL-60 leukemia cells.

    abstract::All-trans-retinoic (ATRA) treatment of patients with acute promyelocytic leukemia results in differentiation of the malignant cells and a high complete remission rate. ATRA treatment induced granulocytic differentiation in HL-60 cells as assessed by nitroblue tetrazolium (NBT) reduction, but had no effect on non-speci...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Hsu HC,Yang K,Kharbanda S,Clinton S,Datta R,Stone RM

    更新日期:1993-03-01 00:00:00

  • LRPAP1 is a frequent proliferation-inducing antigen of BCRs of mantle cell lymphomas and can be used for specific therapeutic targeting.

    abstract::The predominant usage of VH4-34 and V3-21 and reports of stereotyped CDR3s suggest a shared antigenic target of B-cell receptors (BCR) from mantle cell lymphomas (MCL). To identify the target antigens of MCL-BCRs, BCRs from 21 patients and seven MCL cell lines were recombinantly expressed and used for antigen screenin...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/s41375-018-0182-1

    authors: Thurner L,Hartmann S,Fadle N,Kemele M,Bock T,Bewarder M,Regitz E,Neumann F,Nimmesgern A,von Müller L,Pott C,Kim YJ,Bohle RM,Wasik M,Schuster SJ,Hansmann ML,Preuss KD,Pfreundschuh M

    更新日期:2019-01-01 00:00:00

  • Transformation of murine pre-B-lymphocytes by v-erb-B: progression to growth factor independence and tumorigenicity.

    abstract::v-erb-B is the principal transforming gene of avian erythroblastosis virus, a replication defective retrovirus that transforms erythroid and fibroblast cells in vitro and causes erythroleukemia and fibrosarcoma in vivo. We have used a recombinant murine retrovirus, based on the truncated genome of Moloney murine leuke...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Miller M,Kennewell A,Symonds G

    更新日期:1992-01-01 00:00:00

  • Therapy-related myelodysplastic syndrome and acute myeloid leukemia following fludarabine combination chemotherapy.

    abstract::Fludarabine combination chemotherapy achieves high response rates in chronic lymphocytic leukemia (CLL) and indolent lymphoma. The aim of this study was to investigate the incidence and characteristics of treatment-related myelodysplasia and acute myeloid leukemia (t-MDS/AML) after treatment with fludarabine in combin...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2010.218

    authors: Carney DA,Westerman DA,Tam CS,Milner A,Prince HM,Kenealy M,Wolf M,Januszewicz EH,Ritchie D,Came N,Seymour JF

    更新日期:2010-12-01 00:00:00

  • Selected pharmacologic characteristics of idarubicin and idarubicinol.

    abstract::The pharmacology of ID and IDOL are of interest in light of the potential utility of ID in the treatment of adult and pediatric leukemia patients. Preclinical activity and cellular pharmacology of ID were suggestive of greater clinical activity when compared with several standard anthracyclines. Most intriguing were d...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:

    authors: Ames MM,Spreafico F

    更新日期:1992-01-01 00:00:00

  • Genome instability in multiple myeloma.

    abstract::Multiple myeloma (MM) is an incurable plasma cell malignancy characterized by clonal proliferation of plasma cells and a heterogenous genomic landscape. Copy number and structural changes due to chromosomal instability (CIN) are common features of MM. In this review, we describe how primary and secondary genetic event...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:10.1038/s41375-020-0921-y

    authors: Neuse CJ,Lomas OC,Schliemann C,Shen YJ,Manier S,Bustoros M,Ghobrial IM

    更新日期:2020-11-01 00:00:00

  • The WNT receptor ROR2 drives the interaction of multiple myeloma cells with the microenvironment through AKT activation.

    abstract::Multiple myeloma is the second most frequent hematological cancer after lymphoma and remains an incurable disease. The pervasive support provided by the bone marrow microenvironment to myeloma cells is crucial for their survival. Here, an unbiased assessment of receptor tyrosine kinases overexpressed in myeloma identi...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/s41375-019-0486-9

    authors: Frenquelli M,Caridi N,Antonini E,Storti F,Viganò V,Gaviraghi M,Occhionorelli M,Bianchessi S,Bongiovanni L,Spinelli A,Marcatti M,Belloni D,Ferrero E,Karki S,Brambilla P,Martinelli-Boneschi F,Colla S,Ponzoni M,DePinho R

    更新日期:2020-01-01 00:00:00

  • The effect of epidermal growth factor receptor (EGFR) expression on in vivo growth of rat C6 glioma cells.

    abstract::The discovery of EGFR gene amplification in glioblastoma multiforme has prompted interest in experimental therapies to target the receptor on brain tumor cells. To develop an animal model for in vivo study of such strategies, we transfected C6 glioma cells with a plasmid containing the neomycin resistance gene and the...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Fenstermaker RA,Capala J,Barth RF,Hujer A,Kung HJ,Kaetzel DM Jr

    更新日期:1995-10-01 00:00:00

  • Cancer increases risk of in-hospital death from COVID-19 in persons

    abstract::The impact of cancer on outcome of persons with coronavirus disease 2019 (COVID-19) after infection with acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is controversial. We studied 1859 subjects with COVID-19 from seven centers in Wuhan, China, 65 of whom had cancer. We found having cancer was an independent ri...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/s41375-020-0986-7

    authors: Li Q,Chen L,Li Q,He W,Yu J,Chen L,Cao Y,Chen W,Di Wu,Dong F,Cai L,Ran Q,Li L,Liu Q,Ren W,Gao F,Wang H,Chen Z,Gale RP,Hu Y

    更新日期:2020-09-01 00:00:00

  • A 3-day schedule of fludarabine in previously treated chronic lymphocytic leukemia.

    abstract::This study was undertaken to determine the efficacy and toxicity of a shorter schedule of fludarabine administration (30 mg/m2 i.v. daily for 3 days every 4 weeks) in patients with previously treated chronic lymphocytic leukemia (CLL). Eighty patients with previously treated advanced (Rai III-IV) (54%) or progressive ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Robertson LE,O'Brien S,Kantarjian H,Koller C,Beran M,Andreeff M,Lerner S,Plunkett W,Keating MJ

    更新日期:1995-09-01 00:00:00